DekaBank Deutsche Girozentrale
MRSN

DekaBank Deutsche Girozentrale’s Mersana Therapeutics MRSN Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-840
Closed -$195K – 1454
2021
Q3 		$195K Hold
840
– – ﹤0.01% 1213
2021
Q2 		$274K Hold
840
– – ﹤0.01% 1162
2021
Q1 		$326K Hold
840
– – ﹤0.01% 1103
2020
Q4 		$568K Buy
+840
New +$467K ﹤0.01% 995
2018
Q2 		– Sell
-784
Closed -$312K – 1229
2018
Q1 		$312K Sell
784
-416
-35% -$164K ﹤0.01% 939
2017
Q4 		$461K Hold
1,200
– – ﹤0.01% 840
2017
Q3 		$461K Sell
1,200
-800
-40% -$315K ﹤0.01% 846
2017
Q2 		$676K Buy
+2,000
New +$692K 0.01% 776

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DekaBank Deutsche Girozentrale's MRSN Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Mersana Therapeutics (MRSN) in Q4 2021, closing a stake of 840 shares — an estimated $195K sold.

DekaBank Deutsche Girozentrale first reported a position in MRSN in Q2 2017 and held it in 8 quarters. The position peaked at $676K in Q2 2017. 122 funds tracked by Wall St. Rank hold MRSN as of Q4 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Mersana Therapeutics position as of Q4 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 840 Mersana Therapeutics shares in Q4 2021, an estimated $195K.
  • DekaBank Deutsche Girozentrale first reported a position in Mersana Therapeutics in Q2 2017 and held it in 8 quarters.
  • DekaBank Deutsche Girozentrale's Mersana Therapeutics position peaked at $676K in Q2 2017.
  • 122 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.